NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Valaris plc (“Valaris” or “the Company”) (NYSE:VAL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Valaris securities between April 11, 2019 and July 31, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/val.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Valaris was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (2) the foregoing was reasonably likely to have a material negative impact on Valaris’s second quarter 2019 results; (3) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (4) as a result, Valaris’s public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/val or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss Valaris you have until October 21, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557367

HONG KONG / ACCESSWIRE / August 30, 2019 / A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 0690.HK) are pleased to announce that its interim results for the period ended 30 June 2019 (the “Period” or “1H2019”)，During the period, the Group succeeded in turning its loss into profit, with a net profit of HK$44.9 million and a basic profit of HK$0.73 cents per share. Compared with the core performance indicators in the first half of 2018 (“1H2018”), the figures have improved considerably, standing on a turning point of the performance and entering a new phase of growth.

Key Accomplishments in 1H2019

During the Period, The Group has made a series of important progress in sales, corporate governance, Manufacture, R&D and clinical affairs. The key highlights include:

1. During the period, the Group continued to optimize its marketing team and enhance its market penetration. Overall sales rose 63.2% over 1H2018, recording HK$97.3 million. Especially, the sales of recombinant human epidermal growth factor (rhEGF) related drugs from our proprietary biological products were strengthened. The total sales of EGF products were HK$72.1 million, up 54.9% from 1H2018, and their performance accounted for 74.1%. The Group continuously pushes its core products to hospitals at all levels, drug sales terminals and community clinics in key drug-using provinces or municipalities, which greatly promotes the Group’s revenue growth. Among them, 15ml of GeneTime(R) performed best, with sales volume and sales increased significantly, compared with 1H2018, by 89.3% and 93.6% respectively. The increment of GeneSoft(R) recorded 19.6% growth in sales volume and 9.9% growth in sales, respectively.

2. During the period, the contribution of the chemical drug Pinup(R) (Voriconazole Tablets) to the overall sales continued to increase. Single product performance doubled, with revenue of HK$24.0 million. Sales volume and sales increased by 118.3% and 103.8% respectively over 1H2018. Since the end of 2018, the Group has signed a National Promotion Cooperation Agreement with Shanghai Loymed Pharma Technology Co., Ltd. for Pinup(R) Marketing Project. Through close collaboration, the product has entered more than 500 key hospitals in China, which is one of the important reasons for the recovery of growth for this product during this period. In addition, since the Group has completed the consistency evaluation of Pinup(R), compared with most competitors of the same kind without this quality and policy guarantee, the future growth trend will be more stable.

3. During the period, the high-end project of industrialization for tripeptide (rhPTH1-34), supported by government funds, received the first batch of government subsidy of RMB10 million in April 2019. Pursuant to the Public Notice on the 2018 Incubation Programme (Batch II) of High-Tech Industries from the Sub-Parks of the Zhongguancun National Innovation Demonstration Zone, the Major Frontline Innovative Technology Commercialization and Industrialization Project, namely the Industrialization Project of recombinant human Teriparatide (rhPTH1-34) for Injection, which was undertaken and submitted by Beijing GeneTech Pharmaceutical Co., Ltd. (“Beijing GeneTech”), a wholly-owned subsidiary company of the Group, has been approved and recognized by the Zhongguancun Science Park Management Committee. The funds will be used to support the optimization and upgrading of production lines, the protection of independent intellectual property rights and major core technologies, as well as the launch and marketing of this product.

4. During the period, the group completed an organizational restructuring, changing from a divisional structure to a business unit structure. The company formed eight business units that directly report to the new CEO. The new organizational structure is designed to be more streamlined and flat, and focus on better cost control. Especially in the marketing and sales BU, the BU streamlined the structure from 125 employees to around 50 by the end of 2018. Sales expenses over revenue during the period was significantly reduced, down 24.9 percent per revenue point to 74.9% in1H2019.

5. During the period, the R&D cost of the Group was about HK$21.3 million (including capitalized portion), which was used to carry out or complete different R&D projects, including new drug applications for the 2nd generation Uni-E4 exenatide and Uni-PTH tripeptide injection. For the three chemical drugs of the group: Bokangtai (Miglinide Tablets), Boshutai (Acarbose Tablets) and Pinup(R), have reached very significant milestones in the bioequivalence study. Boshutai have completed BE studies and submitted application in January 2019. Pinup(R) have completed BE studies and currently preparing a final filling to the NMPA. Finally, partnering with Jiangsu Hansoh, Bokantai have kicked off bioequivalence study with target to fill in early 2020. In addition, Uni-PTH tripeptide lyophilized powder is in the process of clinical onsite verification and production onsite verification, and is expected to obtain new drug certification and production license from drug regulatory authorities in early 2020.

6. During this period, a new “three in one” biologic fill-finish production line was completed and ready for service in Beijing GeneTech, a wholly-owned subsidiary located in Beijing Zhongguancun Science Park. The production capacity of lyophilized powder in syringe bottle, Cartridge and pre-filled syringe can reach 3,000-8,000 units per hour, 11,000 units per hour and 20 million units per year respectively. It is worth mentioning that, due to the high technical barriers in the production of pre-filling injection,, small and Medium-sized Pharmaceutical Enterprises need to invest a lot of cost and infrastructure to support high-quality production. Therefore, our Group has officially launched the CMO business to the public to save the relevant costs for the partners and bring considerable benefits to the non-core revenue of the Group. At present, Beijing GeneTech has signed two commissioned production contracts and will deliver the products on time.

Prospects

Looking ahead, the Group remains confident in the long-term development of the sector. We believe that the innovation, business diversification and effective resource integration can ensure the substantial and stable development of pharmaceutical enterprises despite regulatory pressures and policy risks. With the reform in the PRC pharmaceutical industry to innovation-oriented and the increasing competitions, drug innovation has become a key growth driver to support sector development in the long run. Over the years, the Group has focused on innovation and R&D for metabolic diseases, such as diabetes, osteoporosis and epidermal growth factor products. The growing age population and increasing health awareness will help the industry with expertise in specific diseases seize growth opportunities. The group’s chronic disease product portfolio with huge market potential will be launched in the near future. In terms of long-term strategic cooperation, two strategic partnership were established in June and July between TimeCity Tourism Development Co., Ltd. in Kaiping, Guangdong Province and CHMT Peaceful Development Fund Management Ltd. in Hong Kong, respectively for the collaboration in chronic disease, deploying health care bases and funding for research on new endocrine drugs. The Group believes that above achievements will lay a solid foundation and drive the development of the Uni-Bio Science Group.

Mr. Kingsley Leung, Chairman of Uni-Bio Science, commented “Looking back on the achievements made by Uni-Bio Science Group in the first half of 2019, the board of directors and I are very pleased to inform our stakeholders that we have ushered in a turning point of performance before the original targeted timeline. We implemented a five-year development plan in 2015 to breakeven by 2020. The good result is from years of hard work from our employees and improvement of our corporate governance. What is more encouraging is the recent recognition by the capital market. Another important strategic investor, CHMT Peaceful Development Fund, made an investment after in-depth due diligence on the company. Also, we have been seeing a very positive performance of our stock price, further showing the increased confidence of shareholders and investors on the Group. Finally, we must realize clearly that we are still undervalued, we are focused to progress our R&D pipeline products to the next value incremental milestone, and show to our stakeholders that we can effectively commercialize these products. Overall, 1H2019 results are encouraging and we will continue this momentum to ensure this success continues in the near future.”

About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

For further information, please contact:
Jacob Zhang
Phone: +86 10 6410 6099
Email: jacob.zhang@uni-bioscience.com

Media archive at www.todayir.com

SOURCE: UNI-BIO SCIENCE GROUP LIMITED

ReleaseID: 557998

NEW YORK, NY / ACCESSWRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Burford Capital Limited (“Burford” or “the Company”) (OTC PINK:BRFRF)(OTC PINK:BRFRY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Burford securities between March 18, 2015 and August 7, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/brfrf.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Burford has been manipulating its metrics, including ROIC and IRR, to create a misleading picture of investment returns to investors; (2) these manipulations hid the fact that the Company is at high risk for a liquidity crunch and is already arguably insolvent; and (3) as a result of the aforementioned misconduct, Defendants’ statements about Burford’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/brfrf or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss Burford you have until October 21, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557364

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Class Period: March 2, 2017 – February 22, 2019
Deadline: September 23, 2019
For more info: www.bgandg.com/kpti

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that material adverse information. The complaint continues to allege that Karyopharm hyped the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured shareholders that it was “well tolerated” by patients. The complaint also states that Karyopharm declared that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Mallinckrodt plc (NYSE:MNK)
Class Period: February 28, 2018 – July 16, 2019
Deadline: September 24, 2019
For more info: www.bgandg.com/mnk

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (2) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

National General Holdings Corp. (NASDAQ:NGHC)
Class Period: August 6, 2015 – August 9, 2017
Deadline: September 23, 2019
For more info: www.bgandg.com/nghc

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) National General, together with banking giant Wells Fargo, had engaged in a massive auto insurance scheme in which National General forced thousands of customers to pay for redundant, unnecessary, and overly expensive Collateral Protection Insurance (“CPI”) that they did not need or want; and (2) while National General was concealing its participation in the fraudulent CPI scheme from investors, they were reporting revenues and earnings results that had been artificially inflated by the illegitimate proceeds from the scheme.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557343

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Omnicell, Inc. (NASDAQGS:OMCL)
Class Period: October 25, 2018 to July 11, 2019
Lead Plaintiff Deadline: September 16, 2019

Omnicell, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in OMCL: http://www.kleinstocklaw.com/pslra-1/omnicell-inc-loss-submission-form?id=3268&from=1.

Carbonite, Inc. (NASDAQGM:CARB)
Class Period: February 7, 2019 to July 25, 2019
Lead Plaintiff Deadline: September 30, 2019

Throughout the class period, Carbonite, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Carbonite’s Server Backup VM Edition was of poor quality and technologically flawed; (ii) Carbonite was receiving poor reviews and complaints from customers about the Server Backup VM Edition; (iii) the poor quality and technological flaws of the Server Backup VM Edition was acting as a “disruptive” factor throughout the Carbonite salesforce and keeping that sales organization from closing opportunistically on several larger deals during fiscal 2019; and (iv) as a result of the foregoing, Carbonite lacked any reasonable basis for issuing its positive projections and financial forecasts.

Learn about your recoverable losses in CARB: http://www.kleinstocklaw.com/pslra-1/carbonite-inc-loss-submission-form?id=3268&from=1.

Cardinal Health, Inc. (NYSE:CAH)
Class Period: March 2, 2015 to May 2, 2018
Lead Plaintiff Deadline: September 30, 2019

During the class period, Cardinal Health, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal’s acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis’s performance were never implemented across Cordis; 2) Cordis’s antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis’s inventory balances; 5) Cordis was not “performing well” and its integration was not “on track,” “going incredibly well” or “largely on plan”; and 6) to correct Cordis’s deficiencies, the Company would have to make substantial investments in Cordis’s IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.

Learn about your recoverable losses in CAH: http://www.kleinstocklaw.com/pslra-1/cardinal-health-inc-loss-submission-form?id=3268&from=1.

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE:The Klein Law Firm

ReleaseID: 557996

CEDARHURST, NY / ACCESSWIRE / August 30, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

CannTrust Holdings Inc. (NYSE:CTST)

Investors Affected : November 14, 2018 – July 12, 2019

A class action has commenced on behalf of certain shareholders in CannTrust Holdings Inc. According to filed complaints, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/canntrust-holdings-inc-loss-submission-form/?id=3269&from=1

Realogy Holdings Corp. (NYSE:RLGY)

Investors Affected : February 24, 2017 – May 22, 2019

A class action has commenced on behalf of certain shareholders in Realogy Holdings Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Realogy was engaged in anticompetitive behavior by requiring property sellers to pay the commissions of a buyer’s broker at an inflated rate; (2) Realogy’s anticompetitive actions would prompt the U.S. Department of Justice (“DOJ”) to open an antitrust investigation into the real estate industry’s practices regarding brokers’ commissions; and (3) as a result, Defendants’ statements about the Realogy’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/realogy-holdings-corp-loss-submission-form/?id=3269&from=1

L Brands, Inc. (NYSE:LB)

Investors Affected : May 31, 2018 – November 19, 2018

A class action has commenced on behalf of certain shareholders in L Brands, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Victoria’s Secret and PINK businesses were having a material adverse effect on the Company’s cash flow, liquidity and debt levels; (b) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (c) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (d) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (e) the representations about L Brands’ disclosure controls in filings the Company made with the SEC were materially false and misleading; (f) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; and (g) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about L Brands’ then-current business operations and future financial
prospects.

Shareholders may find more information at https://kclasslaw.com/securities/l-brands-inc-loss-submission-form/?id=3269&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

ReleaseID: 557997

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Just Energy Group Inc. (NYSE:JE)
Class Period: November 9, 2017 to July 23, 2019
Lead Plaintiff Deadline: September 30, 2019

The complaint alleges that throughout the class period Just Energy Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company experienced customer enrollment and nonpayment issues; (2) as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) as a result, the Company lacked adequate internal control over its financial reporting; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in JE: http://www.kleinstocklaw.com/pslra-1/just-energy-group-inc-loss-submission-form?id=3267&from=1

GTT Communications, Inc. (NYSE:GTT)
Class Period: February 26, 2018 to July 1, 2019
Lead Plaintiff Deadline: September 30, 2019

The lawsuit alleges GTT Communications, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) following GTT’s acquisition of Interoute Communications Holdings S.A., there were delays in migrating Interoute’s legacy systems and processes into GTT’s client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute’s sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT’s core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result of the foregoing, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in GTT: http://www.kleinstocklaw.com/pslra-1/gtt-communications-inc-loss-submission-form?id=3267&from=1

International Flavors & Fragrances Inc. (NYSE:IFF)
Class Period: May 7, 2018 to August 5, 2019
Lead Plaintiff Deadline: October 11, 2019

The lawsuit alleges that International Flavors & Fragrances Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that Frutarom Industries Ltd. (“Frutarom”), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom’s financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in IFF: http://www.kleinstocklaw.com/pslra-1/international-flavors-fragrances-inc-loss-submission-form?id=3267&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 557995

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Venator Materials PLC (NYSE:VNTR)
Class Period: (a) between August 2, 2017 and October 29, 2018, inclusive; (b) in or traceable to the Company’s initial public offering conducted on or around August 3, 2017; and (c) in or traceable to the Company’s secondary public offering conducted on or around December 4, 2017.
Lead Plaintiff Deadline: September 30, 2019

Throughout the class period, Venator Materials PLC allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the fire damage at the Pori facility was far more extensive than disclosed to investors, rendering the facility beyond repair; (b) the true cost of the Pori facility fire exceeded $1 billion, hundreds of millions of dollars beyond the limits of the Company’s insurance policy; (c) the Company was paying rebuilding premiums, and thereby incurring tens of millions of dollars in additional costs, in a futile attempt to expedite the rehabilitation process; (d) Venator had lost, essentially without prospect of rehabilitation, 80% of the production capacity of the Pori facility, and thus lost a substantial portion of one of its largest revenue producing assets; and (e) the Company’s reported annual Titanium Dioxide production capacity had been inflated by approximately 104,000 metric tons, or 15%.

Learn about your recoverable losses in VNTR: http://www.kleinstocklaw.com/pslra-1/venator-materials-plc-loss-submission-form?id=3266&from=1

Netflix, Inc. (NASDAQGS:NFLX)
Class Period: April 17, 2019 to July 17, 2019
Lead Plaintiff Deadline: September 20, 2019

The lawsuit alleges that Netflix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NFLX: http://www.kleinstocklaw.com/pslra-1/netflix-inc-loss-submission-form?id=3266&from=1

Pluralsight, Inc. (NASDAQGS:PS)
Class Period: August 2, 2018 to July 31, 2019
Lead Plaintiff Deadline: October 15, 2019

According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections. In addition, the Company knew at the time of the March 2019 secondary public offering (“SPO”) that it was behind schedule onboarding new sales representatives, which was hurting the Company’s sales execution and preventing Pluralsight from meeting its high growth projections. Instead of disclosing such facts at the time of the SPO, and to cash-out at inflated prices, Defendants intentionally obscured and omitted this pertinent information from investors.

Learn about your recoverable losses in PS: http://www.kleinstocklaw.com/pslra-1/pluralsight-inc-loss-submission-form?id=3266&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 557994

TORONTO, ON / ACCESSWIRE / August 30, 2019 / Zalemark Holding Co. Inc., currently trading on the OTC Markets (OTC PINK:ZMRK), is a U.S. public company, currently domiciled in the State of Delaware.

Management:
Meihua Xu, as CEO and President
Liangjian Peng, as Vice president of Operations
Amanda Zhao, as Vice president of Finance
Jinfu, Zheng as Vice President of Business Development
David Xu, as the CFO

Shareholder Follow Up/Update:

The Company at this time would like to inform all Shareholders that the Company’s Financial Statement are complete at this time. The Company has completed and submitted an OTCIQ Application with the OTC Markets. The Company is currently awaiting completion of the Application Process in order to receive upgraded Login Credentials for the OTC Markets website. If and when the said credentials are received the Company’s Management will immediately upload all Financial Statement with the intention to bring the Company “Current” with the OTC Markets. The Company has received multiple request and inquiries regarding said Financial Statements, so the Company would like to inform all Shareholders at this time that the Statements tentatively will be made public in the very near future.

ZMRK’s CEO, Meihua Xu stated, “I would like to apologize at this time to all the Shareholders for the delays in providing the Financials or Filings, and for the delays in successfully bringing the Company current with the OTC Markets. Completing the Financial Statements or Filings necessary to bring the Company “current” was NO easy task. The previous Management of ZMRK led me to believe that the Financial Books were in order and in good standing. This however, was NOT the case by any means. It took us months to complete the task at hand, not to mention we had very little, if any assistance from some of the previous Officers of the Company. However, with that said, I would like to focus on moving forward, and concentrate more on bringing additional value to the Company.”

ZMRK’s CEO, Meihua Xu also stated, “I want all the Shareholders to know that both operationally and financially, I believe the Company is in good hands, and headed in the right direction. Recently, we have received some inquiries regarding some of the negative comments made about the Company on some of the online forums. In my opinion, these comments or accusations, are coming from people that just want to disrupt forward progress. These comments or accusations are not based on facts. Some of the accusations are so completely absurd, I question where this information comes from all together. The Company will continue to work towards its goals, both financially and operationally. I intend to provide updates to all Shareholders on a more consistent basis, as I believe transparency is best, and is in the best interest of all the Shareholders.”

*Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.’ Statements describing objectives or goals or the Company’s future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Zalemark Holdings Corp Inc.’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Zalemark Holdings Corp Inc. periodic reports filed with the regulatory authorities.

Email: Info@zalemark.com

SOURCE: Zalemark Holding Co. Inc.

ReleaseID: 557989

VANCOUVER, BC / ACCESSWIRE / August 30, 2019 / Dynasty Gold Corp. (TSXV:DYG)(FWB:D5G) (“Dynasty” or the “Company”) is pleased to report that the Ministry of Energy, Northern Development and Mines (ENDM) has acknowledged receipt of the Company’s application for an exploration permit and has sent the application to the Aboriginal communities for consultation. When granted, the exploration permit will allow the Company to conduct drilling on the Property among other activities.

During 2018, two surface programs were completed on targets in the West Contact Zone where previous trenching results returned averaging 8.02 g/t gold over 39.0 meters including impressive 89.4 g/t over 3 meters.

The surface programs in 2018 were to confirm drill targets on the West Contact and Pelham zones, verify and extend the known gold mineralization, confirm rock descriptions and to acquire additional structural data. Historical drill hole data from the Pelham Zone was verified and grade shells were modeled to identify gold mineralization geometry and plunge. Potential drill sites will be confirmed and prioritized based on an extensive review of the geophysical data, and previous and current sampling results.

The Company’s rock chip sampling program conducted in the early summer of 2018 centered on the Glatz Outcrop within the West Contact Zone. It confirmed the mineralization in the West Contact Zone and extended it for an additional 30 meters averaging 3.03 g/t gold.

The mapping and rock sampling program completed in the fall of 2018 focused on the potential trench and drill-target areas around the Glatz outcrop and extended to other parts of the Property where previous IP surveying identified high chargeability and resistivity anomalies. A total of 84 outcrop sites were examined throughout the Property. Assay results from sixty-four grab samples extended the anomalous area. Highlights of the assay results included a grab sample taken near Trench 3 in the north end of the West Contact zone from a silicified mafic volcanic that assayed 4.09 g/t gold, indicating gold potential outside of the younger Temiskaming-like sediments. The silver and telluride pathfinder elements characteristic of the Western Contact area were also elevated.

The press release was reviewed by Andrew Tims, P. Geo, a qualified person under the definition of National Instrument 43-101.

About Thundercloud Property

The Thundercloud Property is located in the central Wabigoon greenstone belt in Western Ontario, 47 kilometres southwest of Dryden. The geological setting is comparable to the Abitibi belt in Eastern Ontario but Thundercloud is much less explored. The Wabigoon belt contains numerous gold showings, several deposits and high grade historic past producers. Regionally, exploration results indicate excellent potential to define bulk-tonnage orogenic gold mineralization as close to 30 M oz of gold has been discovered in recent years, including several large-scale mining operations nearby.

About Dynasty Gold Corp.

Dynasty Gold Corp. is a Canadian gold exploration company currently focused on gold exploration in North America. For more information on the Company and its projects, please refer to the website www.dynastygoldcorp.com.

ON BEHALF OF THE BOARD OF
DYNASTY GOLD CORP.

“Ivy Chong”
Ivy Chong, President & CEO
_________________________________

For additional information please contact:

Vancouver Office:
Ivy Chong
Phone: 604.633.2100
Email: ichong@dynastygoldcorp.com

This press release contains certain “forward-looking statements” that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Dynasty Gold Corp.

ReleaseID: 557985